These results establish for the first time that SEVs-associated α-SynOlig is a promising, sensitive and non-invasive biomarker for PD diagnosis and clinical correlation studies, bearing higher sensitivity than α-SynTot. Moreover, α-SynOlig levels closely followed the clinical outcomes in PD patients. Finally, these findings strengthen the rationale for the further exploration of SEVs to disclose still unavailable accessible biomarkers for multiple neurological diseases.
Gurgone et al. (Wed,) studied this question.